Abstract:Clinical application of anticancer agents has been often hampered by toxicity against normal cells, so the achievement of their cancer-specific action is still one of the major challenges to be addressed. Previously, we reported that arsenic trioxide (As2O3) could be a promising new drug against not only leukemia but also solid tumors. The cytotoxicity of As2O3 occurred through the generation of reactive oxygen species (ROS), thus inhibiting radical scavenging systems would enhance the therapeutic efficacy of As2O3 provided that normal cells were relatively resistant to such a measure. Here, we report that the combination therapy of As2O3 with L-buthionine-sulfoximine (BSO), which inhibits a critical step in glutathione synthesis, effectively enhanced in vitro growth inhibition effect of As2O3 on all 11 investigated cell lines arising from prostate, breast, lung, colon, cervix, bladder, and kidney cancers, compared with As2O3 treatment alone. Furthermore, this combination enhanced cytotoxicity to cell lines from prostate cancer with less toxicity to those from normal prostate. In vitro cytotoxic assay using ROS-related compounds demonstrated that hydrogen peroxide (H2O2) is a major cytotoxic mediator among ROS molecules. Biochemical analysis showed that combined use of As2O3 and BSO blocked H2O2-scavenging systems including glutathione, catalase, and glutathione peroxidase, and that the degree of this blockade was well correlated with intracellular ROS levels and sensitivity to this treatment. Finally, the effectiveness of the combination therapy of As2O3 with BSO was demonstrated with an orthotopic model of prostate cancer metastasis. We propose that the combination therapy of As2O3 with BSO is a valid means of blockade of H2O2-scavenging system, and that the combination of a ROS-generating agent with an inhibitor of major scavenging systems is effective in terms of both efficacy and selectivity. Furthermore, because the effective doses of both compounds are within clinically achievable range, this report will lead to immediate benefit for the development of a new cancer therapy.

[Arsenic Trioxide Combined with Buthionine Sulfoximine Enhances Apoptosis in Multidrug-Resistant Human Leukemia K562/ADM Cells in Vitro].

[The Effect of Arsenic Trioxide (as2o3) Combined with BSO on K562/ADM Cell and Its Mechanisms].

Arsenic Trioxide Induces Not Only Apoptosis but Also Autophagic Cell Death in Leukemia Cell Lines Via Up-Regulation of Beclin-1

[Inhibition Effect of Arsenic Trioxide on the Growth of Human MDS Cell Line MUTZ-1 Cells].

In vitro study of the effect of arsenic trioxide combined with BSO on inhibiting P-glycoprotein expression in K562/ADM cell

[Arsenic Trioxide Inhibits P-glycoprotein Expression in Multidrug-Resistant Human Leukemia K562/ADM Cell Line That Overexpresses Mdr-1 Gene and Enhances Their Chemotherapeutic Sensitivity].

Arsenic trioxide overcomes apoptosis inhibition in K562/ADM cells by regulating vital components in apoptotic pathway.

Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine

Arsenic Trioxide and Artemisinin Act Synergistically to Kill Tumor Cells in Vitro

Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.

[Ascorbic Acid Enhances the Apoptosis of U937 Cells Induced by Arsenic Trioxide in Combination with DMNQ and Its Mechanism].

Effect of Ascorbic Acid Combined with Arsenic Trioxide on Apoptosis and Differentiation in Myelocytic Leukemia Cell Lines

L-Ascorbic Acid and α-Tocopherol Synergistically Triggers Apoptosis Inducing Antileukemic Effects of Arsenic Trioxide via Oxidative Stress in Human Acute Promyelocytic Leukemia Cells

Role of Oxidative Stress in the Apoptosis of Hepatocellular Carcinoma Induced by Combination of Arsenic Trioxide and Ascorbic Acid

Reversal effect of As_2O_3 on inhibition of apoptosis in multidrug-resistant K562/ADM cells

Arsenic Trioxide Inhibits P-Glycoprotein Expression In Multidrug-Resistant Human Leukemia Cells That Overexpress The Mdr1 Gene

Antitumor effect of arsenic trioxide in human K562 and K562/ADM cells by autophagy.

In Vitro Studies on Cellular and Molecular Mechanisms of Arsenic Trioxide (as2o3) in the Treatment of Acute Promyelocytic Leukemia: As2O3 Induces NB4 Cell Apoptosis with Downregulation of Bcl-2 Expression and Modulation of PML-RAR Alpha/pml Proteins

Impact of As_2O_3 on Bcl-2, Survivin and Reactive Oxygen Species (ROS) Expressions during the Process of Induced Apoptosis in Multidrug-Resistant Human Leukemia K562/ADM Cells

Effects of co-administration of arsenic trioxide and Schiff base oxovanadium complex on the induction of apoptosis in acute promyelocytic leukemia cells

Apoptosis Inducing Effects of Arsenic Trioxide on Human Bladder Cancer Cell Line BIU-87.